A Phase 4 interventional study of Placebo and varenicline tartrate in Smoking Cessation, sponsored by Pfizer. Completed at 156 sites in 16 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-10.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.
Among the 110 studies testing varenicline in Smoking Cessation, this one has the largest enrollment, is one of 11 that started in 2011, is one of 47 in phase 4, and was the 62nd registered.
1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.
Browse Smoking Cessation studies →5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 21+
University of Colorado, Denver · Sites in United States, India
Ages 18+
Johns Hopkins University · Sites in South Africa
Ages 18+
University of Maryland, Baltimore · Sites in Botswana
Ages 18+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 25 · Phase 3 30 · Phase 4 47
First in 2000; this study’s year is marked. 11 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8,144 is above the median of 164 across 1,424 interventional studies indexed under Smoking Cessation.
Median enrollment 209 across the 110 interventional studies. Of the 97 that completed or were terminated, 61 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 110 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
44 studies in Smoking Cessation by Pfizer: none open now, none under way, none of them phase 3. Of 43 finished, 23 (53%) have results posted.
Among the 44 studies in Smoking Cessation by Pfizer, this one has the largest enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2011, is one of 11 in phase 4, and was the 40th registered.
Pfizer’s Smoking Cessation studies by the year they started, since 2000.
2 of the studies testing varenicline in Smoking Cessation that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05413122Phase 3Johns Hopkins UniversityEvaluating Smoking Cessation Interventions for PWH in South Africa | 2027-08-31 |
| NCT05694637University of Maryland, BaltimoreBotswana Smoking and Abstinence Reinforcement Trial | 2027-02-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 110 studies testing varenicline in Smoking Cessation, from their registry updates:
Among Pfizer’s 44 in Smoking Cessation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is being conducted to assess varenicline and bupropion as aids to smoking cessation treatment in subjects with and without an established diagnosis of major psychiatric disorder and to characterize the neuropsychiatric safety profile (pre-specified adverse events (AEs) in both of these populations).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with a past or current diagnosis of one of the following disorders:
a. Psychotic Disorders:
Subjects randomized to placebo will receive placebo treatments for all three study drugs. Blinded placebo will be provided for varenicline, bupropion hydrochloride and transdermal nicotine patch (NRT). In addition, subjects will receive blinded placebo treatments for the study drugs they are not randomized to receive.
Drug: Placebo
Drug: varenicline tartrate
Drug: bupropion hydrochloride
Drug: Nicotine Replacement Therapy Patch
Triple dummy placebo for each treatment arm
Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
Also known as: Chantix; Champix
Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
Also known as: NRT
Occurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study Endpoint
The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide.
Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Estimated NPS AE Rate (%), by Cohort
The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis.
Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Occurrence of the Components of the NPS AE Primary Endpoint, Non-psychiatric History Cohort
The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.
Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Occurrence of the Components of the NPS AE Primary Endpoint, Psychiatric History Cohort
The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.
Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Occurrence of the Components of NPS AE Primary Endpoint (Overall)
The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below.
Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Occurrence of Severe-only NPS AEs in the Primary Endpoint, by Cohort
The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Non-psychiatric History Cohort
The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Occurrence of the Components of the Observed Severe-only NPS AE Primary Endpoint, Psychiatric History Cohort
The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Occurrence of the Components of Severe-only NPS AE Endpoint (Overall)
The NPS AE endpoint was the occurrence of at least 1 treatment-emergent "severe" AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent "severe" AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
Time frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Hospital Anxiety and Depression Scale (HADS) Total Score, Non-psychiatric History Cohort
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.
Time frame: Baseline to Week 24
HADS Total Score, Psychiatric History Cohort
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.
Time frame: Baseline to Week 24
HADS Total Score (Overall)
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.
Time frame: Baseline to Week 24
Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Non-psychiatric History Cohort
The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides.
Time frame: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Psychiatric History Cohort
The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.
Time frame: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Positive Responses for Suicidal Behavior and/or Ideation by Columbia Suicide Severity Rating Scale (C-SSRS) - Overall
The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.
Time frame: Lifetime, Baseline and Treatment-Emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Clinical Global Impression of Improvement (CGI-I), "No Change" Rating by Visit
The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as "normal, not at all ill" on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as "no change" on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs.
Time frame: Baseline to Week 24
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).
Time frame: Week 9 through Week 12
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).
Time frame: Week 9 through Week 12
CO-Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall)
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).
Time frame: Week 9 through Week 12
CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).
Time frame: Week 9 through Week 24
CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).
Time frame: Week 9 through Week 24
CO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall)
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).
Time frame: Week 9 through Week 24
7-Day Point Prevalence of Abstinence, Non-psychiatric History Cohort
A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?
Time frame: 24 Weeks
7-Day Point Prevalence of Abstinence, Psychiatric History Cohort
A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?
Time frame: 24 Weeks
7-Day Point Prevalence of Abstinence (Overall)
A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?
Time frame: 24 Weeks
A total of 11,186 participants were screened for participation in the study, of which 3042 participants were considered to be screen failures, leaving 8144 participants eligible for study participation (efficacy population). 86 participants (1.1%) did not receive study drug. A total of 8058 participants received study drug (safety population).
| Milestone | Varenicline | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Started | 2037 | 2034 | 2038 | 2035 |
| Randomized and treated | 2016 | 2006 | 2022 | 2014 |
| Completed | 1598 | 1586 | 1557 | 1552 |
| Not completed | 439 | 448 | 481 | 483 |
| Withdrew: Other reason | 41 | 30 | 36 | 33 |
| Withdrew: No longer meets eligibility criteria | 4 | 8 | 6 | 5 |
| Withdrew: Protocol violation | 4 | 2 | 5 | 5 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 1 |
| Withdrew: Insufficient clinical response | 4 | 4 | 14 | 13 |
| Withdrew: No longer willing to participate | 195 | 218 | 224 | 248 |
| Withdrew: Lost to follow-up | 135 | 126 | 144 | 127 |
| Withdrew: Medication error | 0 | 1 | 0 | 1 |
| Withdrew: Adverse event (study drug) | 25 | 21 | 26 | 17 |
| Withdrew: Adverse event (study drug unrelated) | 9 | 7 | 9 | 9 |
| Withdrew: Death | 0 | 3 | 1 | 3 |
| Withdrew: Randomized but not treated | 21 | 28 | 16 | 21 |
The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide.
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Non-psychiatric cohort (N= 990, 989, 1006, 999) | 1.3 | 2.2 | 2.5 | 2.4 |
| Psychiatric cohort (N= 1026, 1017, 1016, 1015) | 6.5 | 6.7 | 5.2 | 4.9 |
| Overall (N= 2016, 2006, 2022, 2014) | 4.0 | 4.5 | 3.9 | 3.7 |
The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Estimated NPS AE rate (%) was calculated based on least-squares means analysis.
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Non-psychiatric cohort (N=3984) | 1.25 (0.60 to 1.90) | 2.44 (1.52 to 3.36) | 2.31 (1.37 to 3.25) | 2.52 (1.58 to 3.46) |
| Psychiatric cohort (N= 4074) | 6.42 (4.91 to 7.93) | 6.62 (5.09 to 8.15) | 5.20 (3.84 to 6.56) | 4.83 (3.51 to 6.16) |
The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.
| participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Anxiety (severe) | 0 | 1 | 0 | 3 |
| Depression (severe) | 1 | 0 | 0 | 0 |
| Feeling abnormal (severe only) | 0 | 0 | 0 | 0 |
| Hostility (severe) | 0 | 1 | 1 | 0 |
| Agitation (moderate and severe) | 10 | 11 | 19 | 11 |
| Aggression (moderate and severe) | 3 | 3 | 2 | 3 |
| Delusions (moderate and severe) | 0 | 0 | 1 | 0 |
| Hallucinations (moderate and severe) | 1 | 0 | 0 | 0 |
| Mania (moderate and severe) | 0 | 1 | 2 | 2 |
| Panic (moderate and severe) | 0 | 4 | 1 | 3 |
| Paranoia (moderate and severe) | 0 | 1 | 0 | 0 |
| Psychosis (moderate and severe) | 0 | 0 | 1 | 0 |
| Homicidal ideation (moderate and severe) | 0 | 0 | 1 | 0 |
| Suicidal behavior (moderate and severe) | 0 | 1 | 1 | 0 |
| Suicidal ideation (moderate and severe) | 0 | 1 | 2 | 3 |
| Suicide (moderate and severe) | 0 | 0 | 0 | 1 |
The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Each of these 16 components is reported below.
| participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Anxiety (severe) | 5 | 4 | 6 | 2 |
| Depression (severe) | 6 | 4 | 7 | 6 |
| Feeling abnormal (severe only) | 0 | 1 | 0 | 0 |
| Hostility (severe) | 0 | 0 | 0 | 0 |
| Agitation (moderate and severe) | 25 | 29 | 21 | 22 |
| Aggression (moderate and severe) | 14 | 9 | 7 | 8 |
| Delusions (moderate and severe) | 1 | 1 | 1 | 0 |
| Hallucinations (moderate and severe) | 5 | 4 | 2 | 2 |
| Mania (moderate and severe) | 7 | 9 | 3 | 6 |
| Panic (moderate and severe) | 7 | 16 | 13 | 7 |
| Paranoia (moderate and severe) | 1 | 0 | 0 | 2 |
| Psychosis (moderate and severe) | 4 | 2 | 3 | 1 |
| Homicidal ideation (moderate and severe) | 0 | 0 | 0 | 0 |
| Suicidal behavior (moderate and severe) | 1 | 1 | 0 | 1 |
| Suicidal ideation (moderate and severe) | 5 | 2 | 3 | 2 |
| Suicide (moderate and severe) | 0 | 0 | 0 | 0 |
The NPS AE composite results (as previously described) are for the two cohorts combined and are presented below.
| participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Anxiety | 5 | 5 | 6 | 5 |
| Depression | 7 | 4 | 7 | 6 |
| Feeling Abnormal | 0 | 1 | 0 | 0 |
| Hostility | 0 | 1 | 1 | 0 |
| Agitation | 35 | 40 | 40 | 33 |
| Aggression | 17 | 12 | 9 | 11 |
| Delusions | 1 | 1 | 2 | 0 |
| Hallucination | 6 | 4 | 2 | 2 |
| Mania | 7 | 10 | 5 | 8 |
| Panic Disorder | 7 | 20 | 14 | 10 |
| Paranoia | 1 | 1 | 0 | 2 |
| Psychosis | 4 | 2 | 4 | 1 |
| Homicidal Ideation | 0 | 0 | 1 | 0 |
| Suicidal Behavior | 1 | 2 | 1 | 1 |
| Suicidal Ideation | 5 | 3 | 5 | 5 |
| Suicide | 0 | 0 | 0 | 1 |
The primary safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Non-psychiatric cohort (N= 990, 989, 1006, 999) | 0.1 | 0.4 | 0.3 | 0.5 |
| Psychiatric cohort (N= 1026, 1017, 1016, 1015) | 1.4 | 1.4 | 1.4 | 1.3 |
| Overall (N= 2016, 2006, 2022, 2014) | 0.7 | 0.9 | 0.8 | 0.9 |
The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
| participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Anxiety | 0 | 1 | 0 | 3 |
| Depression | 1 | 0 | 0 | 0 |
| Feeling abnormal | 0 | 0 | 0 | 0 |
| Hostility | 0 | 1 | 1 | 0 |
| Agitation | 0 | 0 | 2 | 0 |
| Aggression | 1 | 1 | 0 | 0 |
| Delusions | 0 | 0 | 0 | 0 |
| Hallucinations | 0 | 0 | 0 | 0 |
| Mania | 0 | 0 | 0 | 0 |
| Panic | 0 | 1 | 1 | 1 |
| Paranoia | 0 | 0 | 0 | 0 |
| Psychosis | 0 | 0 | 0 | 0 |
| Homicidal ideation | 0 | 0 | 0 | 0 |
| Suicidal behavior | 0 | 1 | 0 | 0 |
| Suicidal ideation | 0 | 0 | 0 | 1 |
| Suicide | 0 | 0 | 0 | 1 |
The safety endpoint is the occurrence of at least one treatment emergent "severe" adverse event of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least one treatment emergent "moderate" or "severe" adverse event of: agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
| participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Anxiety | 5 | 4 | 6 | 2 |
| Depression | 6 | 4 | 7 | 6 |
| Feeling abnormal | 0 | 1 | 0 | 0 |
| Hostility | 0 | 0 | 0 | 0 |
| Agitation | 1 | 1 | 4 | 2 |
| Aggression | 1 | 1 | 0 | 1 |
| Delusions | 0 | 0 | 0 | 0 |
| Hallucinations | 0 | 1 | 0 | 0 |
| Mania | 2 | 1 | 0 | 0 |
| Panic | 0 | 1 | 0 | 1 |
| Paranoia | 0 | 0 | 0 | 0 |
| Psychosis | 0 | 1 | 1 | 0 |
| Homicidal ideation | 0 | 0 | 0 | 0 |
| Suicidal behavior | 1 | 1 | 0 | 1 |
| Suicidal ideation | 1 | 0 | 1 | 0 |
| Suicide | 0 | 0 | 0 | 0 |
The NPS AE endpoint was the occurrence of at least 1 treatment-emergent "severe" AE of anxiety, depression, feeling abnormal, or hostility and/or the occurrence of at least 1 treatment-emergent "severe" AE of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behavior, or completed suicide. Only those events rated as severe are reported; this excludes any moderate events in the primary NPS AE endpoint.
| participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Anxiety | 5 | 5 | 6 | 5 |
| Depression | 7 | 4 | 7 | 6 |
| Feeling Abnormal | 0 | 1 | 0 | 0 |
| Hostility | 0 | 1 | 1 | 0 |
| Agitation | 1 | 1 | 6 | 2 |
| Aggression | 2 | 2 | 0 | 1 |
| Delusions | 0 | 0 | 0 | 0 |
| Hallucination | 0 | 1 | 0 | 0 |
| Mania | 2 | 1 | 0 | 0 |
| Panic Disorder | 0 | 2 | 1 | 2 |
| Paranoia | 1 | 1 | 0 | 2 |
| Psychosis | 4 | 2 | 4 | 1 |
| Suicidal Behavior | 1 | 2 | 0 | 1 |
| Suicidal Ideation | 1 | 0 | 1 | 0 |
| Suicide | 0 | 0 | 0 | 1 |
| Homicidal Ideation | 0 | 0 | 1 | 0 |
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.
| Units on a scale | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Week 1 (N= 984, 972, 989, 992) | 3.26 ± 3.92 | 3.58 ± 4.25 | 3.06 ± 3.87 | 3.38 ± 4.20 |
| Week 2 (N= 961, 954, 963, 970) | 2.91 ± 3.86 | 3.07 ± 3.96 | 2.84 ± 3.85 | 3.20 ± 4.25 |
| Week 3 (N= 935, 930, 936, 941) | 2.61 ± 3.85 | 2.64 ± 3.82 | 2.63 ± 3.93 | 2.77 ± 3.94 |
| Week 4 (N= 923, 916, 934, 923) | 2.40 ± 3.66 | 2.36 ± 3.57 | 2.46 ± 3.80 | 2.77 ± 4.21 |
| Week 5 (N= 911, 897, 906, 902) | 2.29 ± 3.51 | 2.24 ± 3.52 | 2.32 ± 3.86 | 2.48 ± 3.92 |
| Week 6 (N= 899, 893, 909, 897) | 2.23 ± 3.56 | 2.18 ± 3.57 | 2.40 ± 3.87 | 2.48 ± 3.97 |
| Week 8 (N= 868, 861, 877, 877) | 2.17 ± 3.60 | 2.16 ± 3.70 | 2.28 ± 3.60 | 2.64 ± 4.29 |
| Week 10 (N= 853, 844, 852, 846) | 2.29 ± 3.89 | 1.96 ± 3.24 | 2.33 ± 3.80 | 2.57 ± 4.41 |
| Week 12 (N= 772, 768, 750, 742) | 2.07 ± 3.48 | 1.83 ± 3.21 | 2.01 ± 3.51 | 2.46 ± 4.10 |
| Week 13 (N= 797, 796, 789, 807) | 2.11 ± 3.74 | 1.85 ± 3.22 | 2.01 ± 3.47 | 2.38 ± 4.27 |
| Week 16 (N= 784, 797, 775, 789) | 2.05 ± 3.47 | 1.90 ± 3.43 | 2.09 ± 3.61 | 2.34 ± 3.98 |
| Week 20 (N= 771, 785, 762, 772) | 2.10 ± 3.54 | 1.93 ± 3.36 | 1.97 ± 3.53 | 2.31 ± 4.15 |
| Week 24 (N= 758, 748, 737, 758) | 2.01 ± 3.49 | 1.87 ± 3.47 | 2.01 ± 3.45 | 2.25 ± 4.04 |
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.
| Units on a scale | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Week 1 (N= 1026, 1017, 1015, 1015) | 6.76 ± 6.14 | 7.58 ± 6.87 | 6.82 ± 6.33 | 6.70 ± 5.94 |
| Week 2 (N= 1005, 1004, 996, 995) | 6.42 ± 6.36 | 6.99 ± 6.47 | 6.64 ± 6.55 | 6.42 ± 6.17 |
| Week 3 (N= 947, 961, 945, 926) | 5.99 ± 6.21 | 6.51 ± 6.39 | 6.30 ± 6.55 | 6.02 ± 6.10 |
| Week 4 (N= 935, 938, 929, 908) | 5.87 ± 6.39 | 6.36 ± 6.55 | 6.16 ± 6.51 | 6.04 ± 6.31 |
| Week 5 (N= 918, 918, 914, 895) | 5.58 ± 6.32 | 6.03 ± 6.41 | 5.82 ± 6.44 | 5.80 ± 6.31 |
| Week 6 (N= 917, 914, 912, 874) | 5.39 ± 6.14 | 5.87 ± 6.41 | 5.62 ± 6.22 | 5.75 ± 6.26 |
| Week 8 (N= 887, 893, 878, 859) | 5.43 ± 6.24 | 5.96 ± 6.68 | 5.63 ± 6.36 | 5.63 ± 6.26 |
| Week 10 (N= 864, 865, 864, 823) | 5.38 ± 6.35 | 5.72 ± 6.50 | 5.64 ± 6.30 | 5.55 ± 6.38 |
| Week 12 (N= 790, 803, 798, 749) | 5.17 ± 6.09 | 5.66 ± 6.63 | 5.44 ± 6.30 | 5.42 ± 6.13 |
| Week 13 (N= 813, 812, 814, 763) | 5.06 ± 6.11 | 5.44 ± 6.54 | 5.36 ± 6.20 | 5.09 ± 5.96 |
| Week 16 (N= 795, 805, 791, 748) | 5.26 ± 6.35 | 5.62 ± 6.68 | 5.44 ± 6.34 | 5.37 ± 6.38 |
| Week 20 (N= 784, 784, 763, 737) | 5.17 ± 6.02 | 5.54 ± 6.44 | 5.46 ± 6.18 | 5.26 ± 6.22 |
| Week 24 (N= 770, 764, 758, 729) | 5.21 ± 6.27 | 5.69 ± 6.64 | 5.57 ± 6.32 | 5.04 ± 5.97 |
The HADS is a subject self-reporting scale completed in person at clinic visits at Baseline and Weeks 1 through 6, 8, 10, 12, 13, 16, 20, and 24. It contains 14 individual item responses ranging in increasing severity from 0 (normal) to 3 (most severe) for a total range of 0 to 42. Of the 14 items, 7 assess anxiety and 7 assess depression, providing 2 subscales with ranges of 0 to 21. For each subscale, 0 to 7 is considered normal, while 15 to 21 represents severe symptoms.
| Units on a scale | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Week 1 (N= 1989, 1976, 1985, 1987) | 5.03 ± 5.45 | 5.61 ± 6.07 | 4.95 ± 5.58 | 5.05 ± 5.41 |
| Week 2 (N= 1938, 1937, 1931, 1929) | 4.68 ± 5.55 | 5.06 ± 5.73 | 4.74 ± 5.70 | 4.80 ± 5.53 |
| Week 3 (N= 1882, 1891, 1881, 1867) | 4.31 ± 5.44 | 4.60 ± 5.63 | 4.48 ± 5.71 | 4.38 ± 5.37 |
| Week 4 (N= 1858, 1854, 1863, 1831) | 4.15 ± 5.50 | 4.39 ± 5.65 | 4.31 ± 5.64 | 4.39 ± 5.60 |
| Week 5 (N= 1829, 1815, 1820, 1797) | 3.94 ± 5.37 | 4.16 ± 5.52 | 4.08 ± 5.59 | 4.14 ± 5.51 |
| Week 6 (N= 1816, 1807, 1821, 1771) | 3.82 ± 5.27 | 4.05 ± 5.52 | 4.01 ± 5.42 | 4.09 ± 5.48 |
| Week 8 (N= 1755, 1754, 1755, 1736) | 3.82 ± 5.36 | 4.10 ± 5.75 | 3.96 ± 5.43 | 4.12 ± 5.56 |
| Week 10 (N= 1717, 1709, 1716, 1669) | 3.85 ± 5.49 | 3.86 ± 5.48 | 4.00 ± 5.47 | 4.04 ± 5.67 |
| Week 12 (N= 1562, 1571, 1548, 1491) | 3.64 ± 5.21 | 3.79 ± 5.58 | 3.78 ± 5.42 | 3.95 ± 5.42 |
| Week 13 (N= 1610, 1608, 1603, 1570) | 3.60 ± 5.29 | 3.66 ± 5.47 | 3.71 ± 5.32 | 3.70 ± 5.34 |
| Week 16 (N= 1579, 1602, 1566, 1537) | 3.67 ± 5.37 | 3.77 ± 5.63 | 3.78 ± 5.44 | 3.82 ± 5.50 |
| Week 20 (N= 1555, 1569, 1525, 1509) | 3.65 ± 5.18 | 3.73 ± 5.44 | 3.72 ± 5.33 | 3.75 ± 5.47 |
| Week 24 (N= 1528, 1512, 1495, 1487) | 3.62 ± 5.33 | 3.80 ± 5.64 | 3.82 ± 5.41 | 3.62 ± 5.27 |
The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit.The scale is also used to record any completed suicides.
| participants with positive responses | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Suicidal Behavior (Screening lifetime) | 6 | 9 | 7 | 6 |
| Suicidal Ideation (Screening lifetime) | 48 | 43 | 50 | 49 |
| Suicidal Behavior (Baseline) | 0 | 0 | 0 | 0 |
| Suicidal Ideation (Baseline) | 0 | 1 | 0 | 1 |
| Suicidal Behavior (treatment emergent 12 weeks) | 0 | 0 | 1 | 1 |
| Suicidal Ideation (treatment emergent 12 weeks) | 7 | 4 | 3 | 6 |
The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.
| participants with positive responses | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Suicidal Behavior (Screening lifetime) | 137 | 143 | 111 | 123 |
| Suicidal Ideation (Screening lifetime) | 338 | 357 | 333 | 349 |
| Suicidal Behavior (Baseline) | 0 | 0 | 0 | 1 |
| Suicidal Ideation (Baseline) | 6 | 5 | 2 | 3 |
| Suicidal Behavior (treatment emergent 12 weeks) | 0 | 1 | 0 | 2 |
| Suicidal Ideation (treatment emergent 12 weeks) | 27 | 15 | 20 | 25 |
The C-SSRS is a semi-structured interview designed to evaluate an individual's degree of suicidal ideation, preparatory acts or behavior to actual attempt, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent". Answers at screening are for lifetime history. Answers for all other visits are since last visit. The scale is also used to record any completed suicides.
| participants with positive responses | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Suicidal Behavior (Screening lifetime) | 143 | 152 | 118 | 129 |
| Suicidal Ideation (Screening lifetime) | 386 | 400 | 383 | 398 |
| Suicidal Behavior (Baseline) | 0 | 0 | 0 | 1 |
| Suicidal Ideation (Baseline) | 6 | 6 | 2 | 4 |
| Suicidal Behavior (treatment emergent 12 weeks) | 0 | 1 | 1 | 3 |
| Suicidal Ideation (treatment emergent 12 weeks) | 34 | 19 | 23 | 31 |
The CGI-I is a clinician rated instrument that measures change in participant's psychiatric condition (or lack thereof in the stratum without psychiatric disorders) on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse), with 4 = no change. The ratings were applicable even to those without psychiatric diagnoses (eg, those with no psychiatric symptoms would be rated as "normal, not at all ill" on the CGI-S at baseline and assuming no psychiatric symptoms emerge during the trial, would be rated as "no change" on the CGI-I at follow-up visits). For those participants with a psychiatric diagnosis, the clinician should rate the severity of the mental illness with respect to the clinician's experience with the psychiatric population to which the participant belongs.
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Week 1 (N= 1986, 1974, 1986, 1982) | 94.2 | 93.2 | 94.6 | 95.1 |
| Week 2 (N= 1934, 1936, 1927, 1926) | 90.8 | 90.8 | 90.5 | 91.2 |
| Week 3 (N= 1880, 1892, 1880, 1863) | 88.3 | 89.8 | 88.7 | 87.9 |
| Week 4 (N= 1860, 1856, 1858, 1834) | 86.6 | 88.0 | 87.1 | 86.3 |
| Week 5 (N= 1828, 1816, 1822, 1802) | 85.7 | 86.5 | 85.5 | 85.4 |
| Week 6 (N= 1816, 1808, 1820, 1773) | 85.2 | 86.5 | 85.1 | 84.1 |
| Week 8 (N= 1758, 1756, 1755, 1738) | 82.4 | 83.6 | 82.8 | 81.9 |
| Week 10 (N= 1717, 1707, 1715, 1675) | 80.6 | 81.7 | 80.4 | 79.2 |
| Week 12 (N= 1558, 1572, 1540, 1492) | 72.9 | 75.1 | 72.2 | 71.3 |
| Week 13 (N= 1612, 16081602, 1575) | 75.9 | 76.7 | 75.2 | 74.9 |
| Week 16 (N= 1586, 1606, 1568, 1541) | 74.2 | 76.7 | 73.9 | 73.4 |
| Week 20 (N= 1563, 1573, 1523, 1510) | 73.4 | 75.0 | 72.2 | 71.7 |
| Week 24 (N= 1533, 1515, 1499, 1497) | 71.8 | 72.3 | 71.1 | 71.1 |
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Non-psychiatric History Cohort | 38.0 | 26.1 | 26.4 | 13.7 |
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| CO-Confirmed Continuous Abstinence for Weeks 9 Through 12, Psychiatric History Cohort | 29.2 | 19.3 | 20.4 | 11.4 |
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 12 (inclusive).
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| CO-Confirmed Continuous Abstinence for Weeks 9 Through 12 (Overall) | 33.5 | 22.6 | 23.4 | 12.5 |
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Non-psychiatric History Cohort | 25.5 | 18.8 | 18.5 | 10.5 |
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| CO-confirmed Continuous Abstinence From Week 9 Through Week 24, Psychiatric History Cohort | 18.3 | 13.7 | 13.0 | 8.3 |
A responder to this endpoint requires the answer "no" to both questions 1 and 2 on the Nicotine Use Inventory at every visit from Week 9 to Week 24 (inclusive).
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| CO-confirmed Continuous Abstinence From Week 9 Through Week 24 (Overall) | 21.8 | 16.2 | 15.7 | 9.4 |
A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Week 1 | 1.7 | 1.0 | 1.2 | 1.5 |
| Week 2 | 20.9 | 21.3 | 15.5 | 11.4 |
| Week 3 | 30.0 | 26.6 | 22.1 | 13.6 |
| Week 4 | 34.3 | 27.7 | 25.9 | 14.5 |
| Week 5 | 38.4 | 29.8 | 27.8 | 14.9 |
| Week 6 | 41.0 | 31.4 | 30.4 | 15.9 |
| Week 7 | 44.4 | 35.2 | 35.1 | 19.2 |
| Week 8 | 42.3 | 31.0 | 31.4 | 16.7 |
| Week 9 | 47.1 | 34.9 | 34.8 | 19.0 |
| Week 10 | 42.4 | 31.0 | 31.1 | 16.9 |
| Week 11 | 46.6 | 34.1 | 34.9 | 20.8 |
| Week 12 | 44.4 | 30.5 | 30.4 | 17.8 |
| Week 13 | 41.1 | 30.7 | 29.9 | 17.2 |
| Week 14 | 44.5 | 33.5 | 32.0 | 20.4 |
| Week 15 | 43.8 | 33.2 | 32.4 | 21.3 |
| Week 16 | 37.2 | 28.5 | 28.1 | 18.2 |
| Week 17 | 40.7 | 31.9 | 31.4 | 20.1 |
| Week 18 | 40.9 | 31.3 | 31.7 | 20.8 |
| Week 19 | 39.9 | 31.2 | 31.2 | 20.8 |
| Week 20 | 35.1 | 27.5 | 26.3 | 18.2 |
| Week 21 | 38.1 | 30.3 | 29.3 | 20.1 |
| Week 22 | 38.7 | 29.9 | 29.0 | 20.3 |
| Week 23 | 37.6 | 30.6 | 28.3 | 20.3 |
| Week 24 | 33.6 | 26.0 | 27.0 | 17.4 |
A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Week 1 | 1.0 | 1.2 | 0.7 | 0.5 |
| Week 2 | 16.8 | 14.6 | 13.0 | 9.2 |
| Week 3 | 22.7 | 18.1 | 17.9 | 10.7 |
| Week 4 | 26.6 | 21.3 | 21.1 | 11.8 |
| Week 5 | 28.5 | 21.8 | 22.4 | 12.4 |
| Week 6 | 30.8 | 22.7 | 23.3 | 13.4 |
| Week 7 | 34.8 | 25.4 | 27.5 | 16.6 |
| Week 8 | 32.7 | 22.1 | 24.6 | 15.0 |
| Week 9 | 36.2 | 26.0 | 29.4 | 17.2 |
| Week 10 | 35.1 | 24.3 | 25.0 | 14.0 |
| Week 11 | 38.6 | 27.4 | 29.4 | 17.2 |
| Week 12 | 35.0 | 23.9 | 24.9 | 14.2 |
| Week 13 | 32.7 | 22.6 | 24.0 | 14.8 |
| Week 14 | 34.7 | 25.0 | 26.8 | 17.8 |
| Week 15 | 33.4 | 25.3 | 26.0 | 18.3 |
| Week 16 | 29.1 | 21.9 | 21.8 | 13.9 |
| Week 17 | 32.3 | 24.0 | 24.8 | 17.4 |
| Week 18 | 31.7 | 24.5 | 24.7 | 18.2 |
| Week 19 | 31.6 | 24.7 | 25.1 | 17.6 |
| Week 20 | 26.6 | 20.4 | 25.1 | 17.6 |
| Week 21 | 29.7 | 23.2 | 23.7 | 17.5 |
| Week 22 | 29.1 | 22.9 | 23.6 | 16.5 |
| Week 23 | 28.5 | 23.5 | 22.2 | 16.4 |
| Week 24 | 26.1 | 20.4 | 20.1 | 14.0 |
A responder to this endpoint requires the answer "no" to both questions 3 and 6 on the nicotine use inventory at that specific visit. NUI Question 3 (Baseline through Week 24): Has the subject smoked any cigarettes (even a puff) in the last 7 days? NUI Question 6 (Baseline through Week 12): Has the subject used any other nicotine containing products in the last 7 days? NUI Question 6 (Week 13 through Week 24): Has the subject used any other tobacco products in the last 7 days?
| percentage of participants | Varenicline 1.0 mg BID | Bupropion 150 mg BID | NRT Patch | Placebo |
|---|---|---|---|---|
| Week 1 | 1.3 | 1.1 | 0.9 | 1.0 |
| Week 2 | 18.8 | 17.9 | 14.2 | 10.3 |
| Week 3 | 26.3 | 22.3 | 20.0 | 12.1 |
| Week 4 | 30.4 | 24.4 | 23.5 | 13.1 |
| Week 5 | 33.4 | 25.7 | 25.1 | 13.6 |
| Week 6 | 35.8 | 26.9 | 26.8 | 14.6 |
| Week 7 | 39.5 | 30.2 | 31.3 | 17.9 |
| Week 8 | 37.4 | 26.5 | 28.0 | 15.9 |
| Week 9 | 41.6 | 30.4 | 32.1 | 18.1 |
| Week 10 | 38.7 | 27.6 | 28.0 | 15.5 |
| Week 11 | 42.5 | 30.7 | 32.1 | 18.8 |
| Week 12 | 39.6 | 27.1 | 27.6 | 16.0 |
| Week 13 | 36.8 | 26.5 | 26.9 | 16.0 |
| Week 14 | 39.5 | 29.2 | 29.4 | 19.1 |
| Week 15 | 38.5 | 29.2 | 29.2 | 19.8 |
| Week 16 | 33.1 | 25.1 | 24.9 | 16.1 |
| Week 17 | 36.4 | 27.9 | 28.1 | 18.8 |
| Week 18 | 36.2 | 27.8 | 28.2 | 19.5 |
| Week 19 | 35.7 | 27.9 | 28.1 | 19.2 |
| Week 20 | 30.8 | 23.9 | 23.7 | 16.3 |
| Week 21 | 33.9 | 26.7 | 26.5 | 18.8 |
| Week 22 | 33.8 | 26.4 | 26.3 | 18.4 |
| Week 23 | 33.0 | 27.0 | 25.3 | 18.3 |
| Week 24 | 29.8 | 23.2 | 23.6 | 15.7 |
Collected over From baseline throughout the study period (16 weeks). Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Varenicline 1.0 mg BID | — | 39/2,016 (1.9%) | 1,158/2,016 (57.4%) |
| Bupropion | — | 48/2,006 (2.4%) | 1,033/2,006 (51.5%) |
| NRT Patch | — | 45/2,022 (2.2%) | 1,003/2,022 (49.6%) |
| Placebo | — | 41/2,014 (2%) | 884/2,014 (43.9%) |
| Event | Varenicline 1.0 mg BID | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/2016 | 1/2006 | 4/2022 | 0/2014 |
| Chest painGeneral disorders | 1/2016 | 0/2006 | 4/2022 | 2/2014 |
| AlcoholismPsychiatric disorders | 0/2016 | 3/2006 | 1/2022 | 0/2014 |
| Suicidal ideationPsychiatric disorders | 2/2016 | 1/2006 | 0/2022 | 3/2014 |
| Suicide attemptPsychiatric disorders | 0/2016 | 2/2006 | 1/2022 | 1/2014 |
| Non-cardiac chest painGeneral disorders | 0/2016 | 2/2006 | 1/2022 | 1/2014 |
| Bipolar I disorderPsychiatric disorders | 1/2016 | 2/2006 | 0/2022 | 0/2014 |
| AngioedemaSkin and subcutaneous tissue disorders | 0/2016 | 2/2006 | 0/2022 | 0/2014 |
| Cardiac failure congestiveCardiac disorders | 0/2016 | 0/2006 | 0/2022 | 2/2014 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/2016 | 0/2006 | 0/2022 | 2/2014 |
| Event | Varenicline 1.0 mg BID | Bupropion | NRT Patch | Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 511/2016 | 201/2006 | 199/2022 | 137/2014 |
| Abnormal dreamsPsychiatric disorders | 201/2016 | 131/2006 | 251/2022 | 92/2014 |
| InsomniaPsychiatric disorders | 189/2016 | 245/2006 | 195/2022 | 139/2014 |
| HeadacheNervous system disorders | 245/2016 | 186/2006 | 233/2022 | 199/2014 |
| NasopharyngitisInfections and infestations | 174/2016 | 156/2006 | 126/2022 | 135/2014 |
| AnxietyPsychiatric disorders | 132/2016 | 169/2006 | 137/2022 | 120/2014 |
| Dry mouthGastrointestinal disorders | 66/2016 | 146/2006 | 59/2022 | 64/2014 |
| FatigueGeneral disorders | 124/2016 | 57/2006 | 75/2022 | 83/2014 |
| Upper respiratory tract infectionInfections and infestations | 109/2016 | 104/2006 | 97/2022 | 115/2014 |
| Application site pruritusGeneral disorders | 22/2016 | 12/2006 | 109/2022 | 16/2014 |
The safety analysis population contained all treated participants i.e. who received at least one partial dose of study medication.
| Age, Continuous(Years) | Varenicline 1.0 mg BID | Bupropion | NRT Patch | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 46.5 ± 12.4 | 46.3 ± 12.6 | 46.8 ± 12.2 | 46.4 ± 12.2 | 46.5 ± 12.3 |
| Sex: Female, Male(Participants) | Varenicline 1.0 mg BID | Bupropion | NRT Patch | Placebo | Total |
|---|---|---|---|---|---|
| Female | 1114 | 1116 | 1141 | 1138 | 4509 |
| Male | 902 | 890 | 881 | 876 | 3549 |
Showing the first 100 of 156 sites across 16 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2011, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.
Results were first posted in May 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Varenicline · Bupropion